PULSAR: Clinical Outcomes of Aflibercept 8 mg with Extended Dosing and 2 mg in nAMD in Subgroups Defined by Baseline Characteristics - PubMed
5 hours ago
- #nAMD
- #aflibercept
- #clinical trial
- Study evaluates aflibercept 8 mg with extended dosing vs. 2 mg in nAMD patients based on baseline disease severity.
- Post hoc analysis of PULSAR trial (NCT04423718) with 869 patients completing 96-week treatment.
- Subgroups defined by BCVA, CRT, CNV lesion type, and CNV area.
- Aflibercept 8 mg administered every 12 or 16 weeks after initial monthly doses; intervals adjusted based on disease activity.
- Comparable visual and anatomic outcomes between 8 mg and 2 mg groups across all baseline severity subgroups.
- Most patients on 8 mg maintained extended dosing intervals (≥12 or ≥16 weeks) by week 96.
- Conclusion: Aflibercept 8 mg offers similar benefits to 2 mg but with fewer injections, regardless of baseline severity.